1 Direct therapeutic effect of sulfadoxine-pyrimethamine on nutritional

2 deficiency-induced enteric dysfunction in a human intestine chip

- 3
- 4 Seongmin Kim¹, Arash Naziripour¹, Pranav Prabhala¹, Viktor Horváth¹, Abidemi Junaid¹, David T.
- 5 Breault^{2,3,4}, Girija Goyal¹, Donald E. Ingber^{1,5,6*}
- 6

7	¹ Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115
8	² Department of Pediatrics, Harvard Medical School, Boston, MA 02115
9	³ Department of Endocrinology, Boston Children's Hospital, Boston, MA 02115
10	⁴ Harvard Stem Cell Institute, Cambridge, MA 02138
11	⁵ Vascular Biology Program, Boston Children's Hospital and Department of Pathology, Harvard
12	Medical School, Boston, MA 02115
13	⁶ Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA 02139
14	
15	*Address all correspondence to: don.ingber@wyss.harvard.edu
16	
17	
17	
18	
19	
20	
21	
22	
23	
24	
24	

25 **ABSTRACT**

Sulfadoxine-pyrimethamine (SP) antimalarial therapy has been suggested to improve the birth weight of infants in pregnant women in sub-Saharan Africa independently of malarial infection. Here, we investigated whether SP could have a direct impact on improving intestinal function, thereby enhancing the absorption of essential fats and nutrients crucial for fetal growth.

Using a human organ-on-a-chip model, we replicated the adult female intestine with patient organoid-derived duodenal epithelial cells interfaced with human intestinal endothelial cells. Nutrient-deficient (ND) medium was perfused to simulate malnutrition, resulting in the appearance of enteric dysfunction indicators such as villus blunting, reduced mucus production, impaired nutrient absorption, and increased inflammatory cytokine secretion. SP was administered to these chips in the presence or absence of human peripheral blood mononuclear cells (PBMCs).

Treatment with SP successfully reversed many abnormalities observed in malnourished chips, as confirmed by transcriptomic and proteomic analysis. Notably, SP significantly enhanced intestinal absorptive functions. Furthermore, SP suppressed the recruitment of PBMCs in the nutrient deficient chips. SP may improve the birth weight of children born to malnourished mothers by countering the effects of enteric dysfunction and suppressing inflammation. These findings highlight the possibility of using SP as a direct intervention to improve maternal absorption and subsequently contribute to healthier fetal growth.

43

44 INTRODUCTION

45 Malnutrition during pregnancy, particularly a lack of vital nutrients like iron, fat, calcium, 46 and zinc, can lead to adverse birth outcomes such as low birth weight and developmental delays 47 in children.^{1,2} Low birth weight is also an important indicator of infant mortality, which can be 48 caused by preterm birth, small size for gestational age, and malaria.² To combat malaria infection

49 and reduce the risk of adverse birth outcomes, the World Health Organization (WHO) 50 recommends intermittent preventive treatment with combined sulfadoxine and pyrimethamine (SP) 51 during pregnancy.³ Interestingly, a recent study found that maternal SP treatment can reduce the 52 incidence of low birth weight infants even in the absence of malarial infection and when the 53 organism is resistant to SP treatment.⁴ The physiological relevance of this observation remains 54 unclear as there is limited understanding of the effects of SP treatment on maternal health and 55 birth outcomes.

In this study, we aimed to investigate the effects of SP treatment on nutrient absorption in 56 the adult female small intestine and its impact on intestinal function using functional, 57 transcriptomic, and metabolic assays. To achieve this, we employed a microfluidic human organ-58 59 on-a-chip model of the Intestine (Intestine Chip) that is lined by human intestinal epithelium 60 derived from organoids isolated from the duodenum of young adult females interfaced with 61 primary human intestinal microvascular endothelium. This model allowed us to directly assess the potential therapeutic effects of SP on the intestine. To simulate malnutrition in the adult female 62 intestine, we exposed the Intestine Chip to nutritionally deficient (ND) medium lacking niacinamide 63 and tryptophan. We have previously demonstrated that human Intestine Chips cultured under 64 65 these ND conditions exhibited characteristic signs of environmental enteric dysfunction (EED). such as villus blunting, decreased mucus production, and reduced absorption of fatty acids and 66 peptides, as well as altered transcriptomic profiles, consistent with previous clinical findings in 67 EED patients.⁵ Given the finding that SP seems to increase birth weight in maternal patients who 68 69 are resistant to the anti-malarial effects of this drug,⁴ we administered SP through the apical 70 epithelium-lined channel of the Intestine Chip to mimic oral administration in patients and observed its effects under both healthy and ND conditions. Recognizing the complex interplay 71 between intestinal epithelial cells and the mucosal immune system,^{6,7} we also conducted 72 73 experiments using human peripheral blood mononuclear cells (PBMCs) introduced into the basal

endothelium-lined channel of the Intestine Chips. Our results demonstrate that SP has direct
 protective effects on the malnourished adult female intestine.

76

77 **RESULTS**

78 SP mitigates the effects of nutritional deficiency in the human Intestine Chip

79 In this study, we set out to address the adverse effects of nutritional deficiency (ND) using an Intestine Chip model that faithfully replicates the structure and functionality of the human 80 intestine (figure 1A).⁹ Primary duodenal epithelial cells isolated from patient-derived organoids 81 82 were cultured on the upper extracellular matrix-coated surface of the porous membrane that separates two parallel microchannels within the chips and primary human intestinal microvascular 83 84 endothelium was grown on the lower surface of the same membrane. The culture medium was 85 continuously perfused through both channels while peristalsis-like deformations were produced by the application of cyclic suction to side chambers within the flexible polymer chip. Recreation 86 87 of the intestinal microenvironment in this manner leads to the spontaneous formation of intestinal villi-like structures (figure 1B,C, and supplementary figure 1A). The chip also maintained an intact 88 intestinal barrier (figure 1D) and actively produced mucus (figure 1E,F), including Mucin 5B 89 90 (MUC5B) (figure 1G and supplementary figure 1B).

91 To simulate malnutrition conditions, we perfused the chips with ND medium which lacked the essential nutrients niacinamide and tryptophan. This resulted in villus blunting (figure 1B,C, 92 and supplementary figure 1A), compromised barrier function (figure 1D), and reduced mucus 93 94 production (figure 1E,F, and supplementary figure 1B), as previously described.⁵ Consistent with 95 reduced barrier function, histological and immunofluorescence microscopic analysis revealed that exposure to ND resulted in epithelial and cytoskeletal damage (supplementary figure 1A), as well 96 as partial disruption of VE cadherin-containing endothelial cell-cell contacts (supplementary figure 97 98 1C).

99 Considering the WHO recommendation of a high single dose (500 mg S + 25 mg P) of the 100 SP drug combination during pregnancy, we perfused the epithelial channel of the Intestine Chip 101 with the calculated acute duodenal dose ([133 μ g S + 6·7 μ g P]/mL) of this formulation as well as 102 lower doses (1/50th [2.66 µg S + 0.13 µg P]/mL and 1/10th [13.3 S + 0.67 µg P]/mL) in culture 103 medium and assessed its effects on morphology, barrier function, and cytokine production. We 104 did not observe any significant changes in barrier permeability, epithelial morphology, or inflammatory cytokine production in control Intestine Chips cultured with any of the SP doses 105 when tested in culture medium for three days (supplementary figure 2A-C). In contrast, SP 106 107 treatment resulted in a significant reversal of the ND phenotype in the malnourished Intestine Chip. This was evidenced by increased villus height (figure 1B,C, and supplementary figure 1A), 108 109 improved barrier function (figure 1D), enhanced mucus production (figure 1E,F), and higher levels 110 of MUC5B (figure 1G and supplementary figure 1B). We also noted a reduction in the total number 111 of epithelial cells in the ND condition, which was significantly reversed in the presence of SP 112 (figure 1H).

113 SP increases absorption in nutrient-deficient Intestine Chips

Nutritional components including fatty acids and vitamins help to maintain healthy gut 114 115 homeostasis and prevent intestinal inflammation, and the absorption of fatty acids, zinc, and triglyceride in pregnant women is crucial for normal fetal tissue development and birth 116 outcomes.^{13,14} When RNA-seq analysis of epithelial cells obtained from Healthy Intestine Chips, 117 118 ND chips, and ND chips with SP treatment was carried out, we detected 594 genes (adjusted p < 1119 0.05 and $\log_2(fold change) \ge 1.0$; 149 upregulated, 445 downregulated) that were differentially 120 regulated in the ND condition compared to healthy controls. Intestinal epithelial cells exposed to 121 ND medium exhibited lower expression of lipoproteins (APOA1, APOC3), solute carrier (SLC) transporters (SLC2A5, SLC6A13, SLC28A1), and mucins (MUC2) compared to healthy chip 122 123 controls (figure 2A). Functional enrichment analysis demonstrated that nutritional deficiency

suppressed pathways related to digestion, the triglyceride metabolic process, intestinal absorption, the fatty acid metabolic process, the response to zinc ion, and the vitamin metabolic process, but activated epithelial cell fate commitment and regulation of the Wnt signaling pathway compared with healthy chip controls (figure 2B).

128 In contrast, when we compared transcriptomic expression profiles from SP-treated ND 129 chips to untreated ND chips, we detected differential expression of 50 genes (adjusted p < 0.05130 and $\log_2(\text{fold change}) \ge 1.0$; 11 upregulated, 39 downregulated). The cells from ND+SP chips 131 exhibited higher expression of various genes related to key enzymes in the small intestine 132 (AADAC, NAGS, HMCN2), intestinal mucus homeostasis (CLCA1), a transporter for watersoluble vitamins (SLC52A1), a mediator for iron ion and oxygen binding (HAAO), those involved 133 134 in cell recognition and behaviors (CATSPERD, ZAN, HTR1D), and protein processing (SPON1) during pregnancy compared to the untreated ND condition (figure 2C).¹⁵⁻¹⁸ Functional enrichment 135 136 analysis indicated that cells in SP-treated ND chips reactivated various metabolic processes (water-soluble vitamin, alpha-amino acid, tryptophan, arginine, and lipid), and biological pathways 137 (urea cycle, intestinal smooth muscle contraction, and glutamine biosynthesis), but suppressed 138 regulation of the Wnt signaling pathway, cell morphogenesis, and neuro maturation compared 139 140 with ND chips (figure 2D). Gene set enrichment analysis (GSEA) also showed that genes involved in fatty acid and bile acid metabolism are upregulated in healthy control and ND+SP chips 141 142 compared to ND chips (figure 2E). Consistent with these findings, when we further analyzed cellular uptake of fatty acids using a fluorescently labeled dodecanoic acid, we found a 3.5-fold 143 144 reduction in fatty acid uptake in ND chips compared to healthy chip controls, and treatment with SP significantly reversed this effect (figure 3A,B). 145

146 SP suppresses nutritional deficiency-associated inflammatory responses

147 Malnutrition-associated enteric function also commonly results in enhanced intestinal 148 inflammation.¹⁹ Consistent with this clinical observation, we detected increased protein levels of

multiple pro-inflammatory cytokines, including interleukin-8 (IL-8), MIP-1 α , TNF- α , IFN- γ , IL-10, 149 150 IL-15. REG3A, and lipocalin-2 (LCN2) in ND Intestine Chips compared to healthy control chips 151 (figure 4A,B). Once again, treatment with SP suppressed this inflammatory response by reducing 152 levels of most of these cytokines while further increasing the production of LCN2 (figure 4B). 153 which has been reported to maintain intestinal microbiota homeostasis and protect against 154 intestinal inflammation.²⁰ This increase in inflammation observed in the ND chips was accompanied by epithelial damage and apoptosis, as indicated by increased Caspase-3 155 immunostaining, and again this was reversed by SP treatment (figure 4C,D). Furthermore, when 156 we introduced human peripheral blood mononuclear cells (PBMCs) into the endothelium-lined 157 158 vascular channel of the chip, increased numbers of these immune cells became adherent to the 159 surface of the epithelium in ND chips compared with healthy chip controls. Importantly, this inflammatory recruitment of immune cells was also significantly inhibited by SP treatment (figure 160 4E,F). We also performed flow cytometric analysis of the adherent immune cells, and did not 161 detect any significant changes in the distribution of T cells, B cells, or monocytes under the 162 different experimental conditions (supplementary figure 3). 163

164

165 **DISCUSSION**

The high incidence of low birth weight newborns in women with malnutrition is a critical problem in low-resource nations and a major international issue because it is associated with increased infant mortality and developmental delays in children. The serendipitous finding that SP antimalarial therapy reduces the incidence of lower birth weight infants in pregnant women in sub-Saharan Africa has raised the possibility that this antibiotic combination might have direct effects on maternal physiology that are independent of its antimicrobial actions. In the present study, we investigated this directly by leveraging Organ Chip technology to engineer human Intestine Chips

173 lined with young adult female patient-derived duodenal epithelial cells interfaced with endothelial cells and by mimicking ND using nutrient-reduced growth medium lacking niacinamide and 174 tryptophan. We have previously demonstrated that human Intestine Chips cultured under these 175 176 ND conditions replicate the EED phenotype observed clinically.^{5,21} Importantly, our results show 177 that SP treatment significantly improved conditions of villus blunting, compromised barrier function, 178 mucus layer thinning, and reduced nutrient absorption, and it also prevented epithelial cell death, which are all induced by ND conditions in human Intestine Chips. SP treatment also suppresses 179 180 the release of inflammatory cytokines and inhibits the recruitment of circulating immune cells. 181 Thus, SP does indeed have direct effects on the human adult female intestine that could in part explain the improved birth weights seen in malnourished mothers who were treated with SP as 182 an antimalarial therapy.^{4,22} 183

184 SP appears to alleviate intestinal dysfunction induced by nutritional deficiencies in multiple 185 ways based on our in vitro studies with human Intestine Chips. First, it restores a more normal villus architecture with increased intestinal surface area that is available to absorb digested food 186 molecules. Second, SP treatment of the ND intestine also improves the secretion of mucins and 187 increases the thickness of the intestinal mucus layer that normally lubricates the epithelial surface 188 189 and protects the epithelium from commensal microorganisms, invading pathogens, and other environmental irritants.²³ Third, SP induces the expression of multiple genes that are crucial for 190 the efficient absorption of nutrients and fatty acids, which are extremely important during 191 pregnancy for both maternal and fetal health.²⁴ In particular, we found that ND conditions reduce 192 193 fatty acid absorption in the intestinal epithelium and that treatment with SP counters this inhibition. Genes involved in fatty acid uptake, transport, and metabolism, which are important for 194 maintaining both glucose and energy homeostasis,²⁵ are also downregulated in the ND condition 195 compared with healthy controls, and again SP treatment largely reverses this effect. Interestingly, 196 197 we found that SP treatment stimulates the metabolism of bile acids, which are known to play

multiple roles in lipid metabolism and serve as signaling molecules in the small intestine by modulating lipid, glucose, and energy homeostasis, in addition to supporting the absorption of dietary lipids.

201 In the living intestine, there is an intricate interplay between intestinal epithelial cells and 202 the mucosal immune system.²⁶ which becomes deregulated leading to increased inflammation in 203 patients with EED or other forms of intestinal dysfunction. Similarly, we found that culturing healthy 204 Intestine Chips lined by epithelium from young adult female donors in the presence of ND medium 205 resulted in increased production of multiple pro-inflammatory cytokines, which is consistent with 206 what we observed previously in chips lined by cells from EED patients when exposed to nutritional 207 deficiency.⁵ Interestingly, after SP treatment, these elevated cytokine levels in the ND Intestine 208 Chips reduced significantly when the chips were treated with SP. The only exception was LCN2, 209 which was induced by SP. This is interesting because LCN2 is known to suppress inflammation 210 in the intestine by multiple mechanisms including protecting the barrier against oxidative stress, enhancing phagocytic bacterial clearance, maintaining homeostasis with the commensal 211 microbiome, and modulating immune responses.²⁷ Consistent with these observations, we found 212 that when we introduced PBMCs into the endothelium-lined vascular channel of the Intestine 213 214 Chips, ND increased immune cell recruitment whereas SP treatment greatly reduced this 215 response.

Taken together, these results show that SP can indeed have multiple direct effects on human intestinal structure and function that could explain the serendipitous observation of reduced incidence of low birth weight newborns, which is seen in pregnant women after antimalaria treatment with SP. Most importantly, these findings suggest that SP should be further explored as a potential treatment for this important global health issue, and that the human Intestine Chip also may prove useful to address other questions relating to intestinal physiology and pathophysiology that are of interest to the global health community.

223 METHODS

224 Preparation of Intestine Chips and SP treatment

225 Intestinal organoids were generated from biopsy samples from healthy regions of the duodenum in patients being evaluated for potential other intestinal problems, as described.^{5,8} and 226 227 all methods were performed according to the approval of the Institutional Review Board of Boston 228 Children's Hospital (Protocol number IRB-P00000529). Our methods for culturing patient-derived 229 epithelial intestinal organoids, enzymatically releasing the cells, and then culturing them within 230 one channel of a two-channel microfluidic organ chip device (Emulate Inc.) separated by a porous 231 membrane from primary human microvascular endothelial cells in the second channel, have been described previously.^{5,9} The upper epithelial channel was perfused with complete medium or ND 232 233 medium without niacinamide and tryptophan at 60 µL/h to mimic the EED state, while the lower 234 channel was perfused with expansion culture medium. Sulfadoxine (S; 200 mg, USP) and 235 pyrimethamine (P; 200 mg, USP) were prepared in 0.5 mL DMSO (ThermoFisher), and mixed with differentiation medium (DM) at a ratio of 20:1 (133 µg S + 6.7 µg P)/mL which simulates the 236 acute duodenal exposure at the WHO recommended dose (500 mg S + 25 mg P/tablet) of the SP 237 formulation (192 µg S + 9.6 µg P)/chip for 1 day; equivalent to 1 SP tablet in 250 mL gastric 238 239 volume considering the gastric volume of a healthy adult (250-300 mL); these drugs were then 240 perfused through the epithelial channel for 3 days.

241 Morphological analysis

For immunofluorescence microscopic imaging, tissues within either whole or Vibratome (Leica VT1000S) sectioned chips were fixed with 4% paraformaldehyde (PFA), permeabilized, and blocked with 0.1% Triton X-100 solution and 10% donkey serum in PBS. Barrier integrity was assessed using antibodies directed against ZO-1 (Invitrogen, 33-9100), VE-Cadherin (ThermoFisher, ab33168), and species-specific secondary antibodies (Invitrogen, A31570 and

Invitrogen, A31571); nuclei were stained with Hoechst 33342 (Invitrogen, H3570). Pseudo
 hematoxylin and eosin (H&E) staining was carried out on 40-60 µm chip sections, as described.
 ¹⁰ Imaging was carried out using a laser scanning confocal microscope (Leica SP5 X MP DMI 6000), and IMARIS (Ver. 9.9.1, Oxford Instruments) and ImageJ software were used for
 processing and analysis of 3D high-resolution horizontal or vertical cross-sectional images.

252 Intestinal barrier permeability

We assessed the paracellular permeability of the intestinal barrier within Intestine Chips as previously described using the small fluorescent biomarker, Cascade Blue (596 Da; ThermoFisher, C687).¹¹ Briefly, the apical-to-basolateral flux of the paracellular marker was calculated using the following formula: $P_{app} = (V_r \times C_r)/(t \times A \times Cd \text{ out})$, where V_r is the volume of the receiving channel outflow, C_r is the concentration of tracer in the receiving channel, *t* is time (sec), *A* is the total area of diffusion (cm²), and *Cd out* is the concentration of tracer in the dosing channel outflow (mg/mL).

260 Mucus accumulation

261 Intestinal mucus was visualized on-chip using wheat germ agglutinin (WGA)-Alexa 488 (ThermoFisher).⁵ Briefly, 25 µg/mL of WGA in Hanks' Balanced Salt Solution (HBSS, Gibco) was 262 flowed at 200 µL/h through the apical channel for 30 min and then washed with continuous flow 263 264 of HBSS at the same flow rate for 30 min. The entire channel was visualized with a fluorescence 265 microscope (Excitation/Emission=488/523nm, Zeiss Axio Observer Z1). For MUC5B visualization, immunofluorescence microscopic imaging was carried out on 150-200 µm chip sections using 266 antibodies against MUC5B (Invitrogen, 37-7400) and a secondary antibody (ThermoFisher, 267 268 A31571). The MFI intensity of MUC5B staining was guantified using ImageJ.

269 Fatty acid uptake

270

Fatty acid (FA) absorption was measured as described.⁵ Briefly, the media in the apical

and basal channels of the Intestine Chips were switched to HBSS for 1 h. A fluorescently labeled dodecanoic acid containing a quencher (10 μ L quencher + 5 μ L FA + 485 μ L assay buffer + 500 μ L HBSS) was then added to the apical channel according to the manufacturer's instructions (BioVision, K408). Fluorescence microscopic imaging of the epithelial channel was then carried out (Excitation/Emission=488/523nm, Zeiss Axio Observer Z1 and Echo Revolve microscope) and FA uptake was calculated by determining fluorescence intensity levels using ImageJ.

277 Transcriptomic analysis

278 RNA sequencing analysis of epithelial cells removed from the chips by exposure to 279 Accumax[™] (STEMCELL Technologies) was performed by AZENTA Life Sciences (NJ, USA). 280 Briefly, RNA was isolated using RNeasy Plus Micro Kit (Qiagen) and the samples were evaluated for RNA quality. Libraries were sequenced using the Illumina HiSeq4000 platform, and the 281 282 resulting150bp long pair-ended reads were trimmed using Trimmomatic (v.0.36) mapped to 283 GRCh38 reference genome using STAR (v.2.5.2); gene hit counts to ENSEMBL Release 105 284 transcriptome annotation were generated using featureCounts of Subread package (v.1.5.2) for downstream analysis. Differential gene expression analysis was performed using DESeq2 285 (v.1.26.0) with the Benjamini and Hochberg method for adjusting p-values for multiple hypothesis 286 287 testing. Genes with adjusted p-values < 0.05 and absolute $\log_2(fold change) \ge 1$ were considered 288 differentially expressed. Relevant biological pathways were identified in the MSigDB Hallmark 2020 database using gene set enrichment analysis (GSEA).¹² 289

290 Inflammatory cytokine production

291 Changes in cytokine levels were measured in apical channel effluents from our chips.¹¹ 292 Ten inflammatory cytokines were selected and a Luminex assay was conducted according to the 293 manufacturer's protocol (Invitrogen). Analyte concentrations were measured using a Luminex 294 FLEXMAP 3D instrument with xPONENT® software. For apoptosis analysis, cleaver Caspase-3

(Cell Signaling Technology, 9661S) was stained with a secondary antibody (ThermoFisher,
 A31572) and imaged with a laser scanning confocal microscope (Leica); the fluorescence
 intensity was measured using ImageJ.

298 Immune cell recruitment

299 We quantified the effects of SP on the recruitment of immune cells through the 300 endothelium and to the epithelium by perfusing PBMCs through the lower endothelium-lined 301 channel, as previously described.¹¹ Briefly, de-identified human patient-derived apheresis collars were obtained from the Crimson Biomaterials Collection Core Facility under approval obtained 302 303 from the Institutional Review Board at Harvard University (#22470). Cells were stained with 304 CellTracker Green[™] CMFDA (1:1,000 v/v in PBS, ThermoFisher, #C7025) for 10 min at 37°C in 305 a water bath and stained PBMCs were then seeded into the basal channel (endothelium) of the 306 Intestine Chips at 5×10^7 cells/mL in medium. PBMCs were allowed to adhere to the endothelium 307 by inverting the chips for 3 h under a static condition, were gently washed with complete medium 308 to remove non-adherent or suspended cells, and were then maintained at continuous flow (60 µL/h). The number of PBMCs that adhered and migrated from the basal vascular channel to the 309 apical epithelium-lined channel was quantified by immunofluorescence microscopic imaging. The 310 311 composition of these PBMCs recruited to the epithelium was determined using Flow Cytometry 312 (CytoFlex LX); cell digests were stained with Viakrome 808 Live/Dead stain (Beckman Coulter, 313 C36628), CD19 BV421 (BioLegend, 302234), CD3 APC-H7(BD Biosciences, 560176), and CD14 BV395 (BD Biosciences, 563561), and then fixed with 200 µL of Cytofix (BD Biosciences, 554655). 314 315 To calculate the absolute number of cells per sample, 5025 counting beads were added to each 316 sample. Results were analyzed using FlowJo V10 software (FlowJo, LLC).

317 Statistical analysis

318

Between 3 and 6 Intestine Chips were used in each study and a Two-tailed Student's t-

- 319 test was performed to determine statistical significance, as indicated in the figure legends. P <
- 0.05 were considered significant; error bars indicate mean ± standard deviation (s.d.).

331 **REFERENCES**

Gernand AD, Schulze KJ, Stewart CP, West KP, Jr., Christian P. Micronutrient deficiencies in
 pregnancy worldwide: health effects and prevention. *Nat Rev Endocrinol* 2016; **12**(5): 274-89.

2. Abu-Saad K, Fraser D. Maternal nutrition and birth outcomes. *Epidemiol Rev* 2010; **32**: 5-25.

Deloron P, Bertin G, Briand V, Massougbodji A, Cot M. Sulfadoxine/pyrimethamine intermittent
 preventive treatment for malaria during pregnancy. *Emerg Infect Dis* 2010; **16**(11): 1666-70.

4. Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. *JAMA* 2013; **309**(6): 594-604.

Bein A, Fadel CW, Swenor B, et al. Nutritional deficiency in an intestine-on-a-chip recapitulates
injury hallmarks associated with environmental enteric dysfunction. *Nat Biomed Eng* 2022; 6(11): 123647.

343 6. Soderholm AT, Pedicord VA. Intestinal epithelial cells: at the interface of the microbiota and
344 mucosal immunity. *Immunology* 2019; **158**(4): 267-80.

345 7. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease.
346 *Cell Res* 2020; **30**(6): 492-506.

Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human
 colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* 2011; **141**(5): 1762-72.

Kasendra M, Tovaglieri A, Sontheimer-Phelps A, et al. Development of a primary human Small
 Intestine-on-a-Chip using biopsy-derived organoids. *Sci Rep* 2018; **8**(1): 2871.

Belfer KN, Sholl AB, Wang M, et al. DRAQ5 and Eosin ('D&E') as an Analog to Hematoxylin and
 Eosin for Rapid Fluorescence Histology of Fresh Tissues. *PLoS One* 2016; **11**(10): e0165530.

Bein A, Kim S, Goyal G, et al. Enteric Coronavirus Infection and Treatment Modeled With an
Immunocompetent Human Intestine-On-A-Chip. *Front Pharmacol* 2021; **12**: 718484.

Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005; **102**(43):
15545-50.

Morrison JL, Regnault TR. Nutrition in Pregnancy: Optimising Maternal Diet and Fetal
 Adaptations to Altered Nutrient Supply. *Nutrients* 2016; **8**(6).

Vrijkotte TG, Algera SJ, Brouwer IA, van Eijsden M, Twickler MB. Maternal triglyceride levels
during early pregnancy are associated with birth weight and postnatal growth. *J Pediatr* 2011; **159**(5):
736-42 e1.

363 15. Geng M, Li T, Kong X, et al. Reduced expression of intestinal N-acetylglutamate synthase in
364 suckling piglets: a novel molecular mechanism for arginine as a nutritionally essential amino acid for
365 neonates. *Amino Acids* 2011; **40**(5): 1513-22.

Mosegaard S, Bruun GH, Flyvbjerg KF, et al. An intronic variation in SLC52A1 causes exon
 skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. *Mol Genet*

368 *Metab* 2017; **122**(4): 182-8.

Amir Shaghaghi M, Bernstein CN, Serrano Leon A, El-Gabalawy H, Eck P. Polymorphisms in the
 sodium-dependent ascorbate transporter gene SLC23A1 are associated with susceptibility to Crohn
 disease. *Am J Clin Nutr* 2014; **99**(2): 378-83.

Hong W, Guo F, Yang M, et al. Hydroxysteroid sulfotransferase 2B1 affects gastric epithelial
 function and carcinogenesis induced by a carcinogenic agent. *Lipids Health Dis* 2019; **18**(1): 203.

374 19. Guerrant RL, Oria RB, Moore SR, Oria MO, Lima AA. Malnutrition as an enteric infectious disease
375 with long-term effects on child development. *Nutr Rev* 2008; **66**(9): 487-505.

Moschen AR, Gerner RR, Wang J, et al. Lipocalin 2 Protects from Inflammation and
 Tumorigenesis Associated with Gut Microbiota Alterations. *Cell Host Microbe* 2016; **19**(4): 455-69.

Nyaradi A, Li J, Hickling S, Foster J, Oddy WH. The role of nutrition in children's neurocognitive
development, from pregnancy through childhood. *Front Hum Neurosci* 2013; **7**: 97.

ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy
 of intermittent preventive therapy for malaria control during pregnancy: a systematic review. *JAMA* 2007;
 297(23): 2603-16.

383 23. Grondin JA, Kwon YH, Far PM, Haq S, Khan WI. Mucins in Intestinal Mucosal Defense and
384 Inflammation: Learning From Clinical and Experimental Studies. *Front Immunol* 2020; **11**: 2054.

24. Duttaroy AK, Basak S. Maternal dietary fatty acids and their roles in human placental
development. *Prostaglandins Leukot Essent Fatty Acids* 2020; **155**: 102080.

25. Rui L. Energy metabolism in the liver. *Compr Physiol* 2014; **4**(1): 177-97.

Takiishi T, Fenero CIM, Camara NOS. Intestinal barrier and gut microbiota: Shaping our immune
 responses throughout life. *Tissue Barriers* 2017; 5(4): e1373208.

Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial
 infection by sequestrating iron. *Nature* 2004; **432**(7019): 917-21.

392

393

394

395

396

397

399 Acknowledgments

This study was funded by the Bill and Melinda Gates Foundation and the Wyss Institute for Biologically Inspired Engineering at Harvard University. We would like to thank Thomas C. Ferrante and Alican Ozkan for their help in processing the images. We also thank Gwenn E. Merry for editing this manuscript.

404 Contributors

- 405 S.K. led this study, and S.K., G.G., and D.E.I. designed the overall research. S.K., A.N., and P.P.
- 406 performed experiments. S.K., V.H., A.J., G.G., and D.E.I. analyzed and interpreted all the data.
- 407 D.T.B. established human intestinal organoids. S.K. and D.E.I. wrote the article with input from
- 408 other authors.

409 Data sharing

- 410 The datasets and analysis will be available upon request. All requests should be addressed to the
- 411 corresponding author (don.ingber@wyss.harvard.edu).

412 **Declaration of interests**

- 413 D.E.I. holds equity in Emulate, Inc., chairs its scientific advisory board, and is a member of its
- 414 board of directors. The other authors declare no competing interests.

415 **FIGURE LEGENDS**



416

Figure 1: Effect of nutritional deficiency and SP treatment on adult female Intestine Chip (A) A schematic cross-sectional view of the duodenal organoid-derived Intestine Chip showing the apical (epithelium) and basal (endothelium) microchannels. The sulfadoxine-pyrimethamine (SP) drug combination was applied to the apical channel and the human peripheral blood mononuclear cells (PBMCs) were applied to the basal channel. (B) Immunofluorescence imaging of cross-

sectioned Intestine Chips showing villus-like structures, green: phalloidin, yellow: ZO-1, blue: 422 Hoechst 33342. Scale bar = 50 µm. (C) Differences in villus-like structure height between normal 423 (Con), nutritionally deficient (ND), and SP-treated ND (ND+SP) Intestine Chips. **p < 0.01, ****p424 425 < 0.0001 by Two-tailed Student's t-test. (D) Apparent permeability (P_{app}) after SP treatment. *p < 426 0.05, ***p < 0.001 by Two-tailed Student's t-test. (E) Immunofluorescence imaging of Intestine Chips stained with wheat germ agglutinin (WGA) with Alexa-488 conjugated lectin showing mucus 427 production. Scale bar = 200 μ m. (F) Differences in fluorescence intensity of WGA. **p < 0.01, ***p428 < 0.001, ****p < 0.0001, by Two-tailed Student's t-test. (G) Differences in fluorescence intensity 429 of MUC5B. ***p < 0.001 by Two-tailed Student's t-test. (H) Comparison of cell number between 430 Con, ND, and ND+SP Intestine Chips. *p < 0.05, ***p < 0.001 by Two-tailed Student's t-test. 431





Figure 2: Reversal of impaired absorption in nutrient-deficient Intestine Chips by SP treatment (A) Volcano plot of DEGs from nutritionally deficient (ND) chips compared to control (Con) chips. (B) Dot plot showing the biological processes activated or suppressed by ND vs. Con conditions from (A). (C) Volcano plot of DEGs found in epithelial cells from SP-treated ND chips (ND+SP) compared to those from ND chips. (D) Dot plot showing the biological processes

- activated or suppressed by ND+SP vs. ND condition from (C). (E) Gene Set Enrichment Analysis
 (GSEA) plots showing the significant enrichment of gene sets in epithelial cells from Con vs. ND
 and from ND+SP vs. ND conditions, respectively. MSigDB Hallmark 2020 was used for GSEA
 plot.
- 442
- 443



Figure 3: Impaired fatty acid absorption (A) Fatty acid (FA) absorption assay in the Intestine Chips by fluorescently-labeled (Alexa 488) dodecanoic fatty acid uptake at the 60 min time point. Scale bar = 50 μ m. (B) Differences in fluorescence intensity of up-taken FA. ***p* < 0.01, ****p* < 0.001, *****p* < 0.0001 by Two-tailed Student's t-test.





Figure 4: Effect of SP on inflammatory responses associated with nutritional deficiency (A) Heatmap showing differential expression of 10 cytokines secreted into the apical (epithelium) channel of Intestine Chips at day 3 after SP treatment, measured by Luminex assay. The colorcoded scale represents the log₂ fold change in expression. (B) Production of four key cytokines on day 1, day 2, and day 3 after SP treatment. White (Con), gray (ND), and dark gray (ND+SP). *p < 0.05, **p < 0.01, ***p < 0.001 by Two-tailed Student's t-test. (C) Immunofluorescence imaging

- 456 of the epithelial channel of Intestine Chips stained for Caspase-3 (white) and Hoechst 33342
- 457 (blue). Scale bar = 100 μm. (D) Differences in fluorescence intensity of Caspase-3 from Intestine
- 458 Chip images (C). *p < 0.05, by Two-tailed Student's t-test. (E) Recruitment of PBMCs in the
- 459 Intestine Chip. PBMCs were stained with CellTracker Green[™] CMFDA. Scale bar = 50 μm. (F)
- 460 Quantification of recruited PBMCs in the top channel of chips from Intestine Chip images (E). *p
- 461 < 0.05, ***p < 0.001 by Two-tailed Student's t-test.

462 Supplementary Data



Supplementary Figure 1: Morphological characteristics of Intestine Chips (A) Pseudo-H&E stained images of the intestinal epithelium on Intestine Chips. Red arrows indicate regions of potentially damaged epithelium and pseudostratified cytoskeleton. Scale bar = 50 μ m. (B) Immunofluorescence imaging of cross-sectioned Intestine Chips showing the presence of mucin, red: MUC5B, blue: Hoechst 33342. Scale bar = 50 μ m. The fluorescence intensity of MUC5B is shown in figure 1G. (C) Immunofluorescence imaging of the basal channel (endothelium) of Intestine Chips stained with VE-Cadherin (white) and Hoechst (gray). Scale bar = 50 μ m.



472 Supplementary Figure 2: Optimal dose-finding for an Intestine Chip model (A) Phase-contrast imaging 473 of Intestine Chips. Intestine Chips were treated with DMSO only (control) or different doses of SP dissolved 474 in DMSO. The epithelial channel of the Intestine Chip was perfused with the calculated acute duodenal 475 dose ([133 μ g S + 6.7 μ g P]/mL) of this formulation as well as lower doses (1/50th [2.66 μ g S + 0.13 μ g 476 P]/mL and 1/10th [13.3 S + 0.67 µg P]/mL) in culture medium. Scale bar = 100 µm. (B) Apparent 477 permeability (*P*_{app}) after SP treatment with different doses. (C) Cytokine analysis at day 1, day 2, and day 478 3 after SP treatment was measured by Luminex assay in the effluent from the apical (epithelium) channel 479 of Intestine Chips. *p < 0.05 by Two-tailed Student's t-test.



480

481 Supplementary Figure 3: Composition of recruited immune cells. PBMCs were collected from Intestine

482 Chips and identified by FACS. Orange (T-cells by CD3), green (Monocytes by CD14), and blue (B-cells by

483 CD19).